FDA Determines Regulatory Review Period for XOFIGO Patent Extension

Summary

The U.S. Food and Drug Administration (FDA) has officially confirmed the regulatory review period for XOFIGO, a pharmaceutical company, in accordance with federal regulations, following the submission of a patent extension application to the U.S. Patent and Trademark Office (USPTO).